The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis

Surgery Today

Volumn 45, Issue 12, 2015, Pages 1527-1534

  Schreckenbach, Teresa ^a   Malkomes, Patrizia ^a   Bechstein, Wolf O ^a   Woeste, Guido ^a   Schnitzbauer, Andreas A ^a   Ulrich, Frank ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Clinical risk scores; Colorectal cancer; Fong; Liver metastases; Nordlinger; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; GERMANY; HIGH RISK POPULATION; HUMAN; LIVER RESECTION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK ASSESSMENT; RISK FACTOR; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; RISK; SECONDARY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; GERMANY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 84947488807     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-014-1108-9     Document Type: Article

References (16)

1. Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion. 1969;2:179–86.
2. Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–9.
3. Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Ärztebl Int. 2010;107:335–42.
4. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2009;1(27):3677–83.
5. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20:985–92.
6. Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.
7. Amano R, Yamada N, Nakata B, Kimura K, Yoshiro M, Ohira M, Hirakawa K. A prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today. 2014;44(7):1287–92.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18 (discussion 318–321).
9. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;1(77):1254–62.
10. Belgihiti J, Clavien PA, Gadzijev E, Garden JO, Lau W, Makuuchi M. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333–9.
11. Folprecht G, Gruenberger T, Bechstein W, Raab H-R, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25(5):1018–25.
12. Hamady ZZR, Lodge JPA, Welsh FK, Toogood GJ, White A, John T, et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg. 2014;259:543–8.
13. Ayez N, Lalmahomed ZS, van der Pool AEM, Vergouwe Y, van Montfort K, de Jonge J, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18:2757–63.
14. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:3279–88.
15. Merkel S, Bialecki D, Meyer T, Müller V, Papadopoulos T, Hohenberger W. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;1(100):349–57.
16. Maithel SK, Gönen M, Ito H, Dematteo RP, Allen PJ, Fong Y, et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012;151:162–70.